Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm

Martínez‐Marcos, Francisco Javier; García-Garmendia, José Luis; Ortega-Carpio, Antonio; Fernández-Gómez, Juan Manuel; Santos, J.M. García; Camacho, Crescencio

doi:10.1016/s0002-9149(00)01128-0

Cited by 153 publications

(90 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17,18 In some other reports, the conversion rate in the amiodarone-treated patients assessed within 8 h of therapy was similar and did not exceed 59%. 6,9,14 Lack of difference between efficacy of amiodarone and control treatment during the first 8 h of therapy may be explained in part by the above-mentioned delayed onset of amiodarone class III antiarrhythmic action, and in part by the well-known fact that the highest rate of spontaneous termination of AF is seen within the first 8 h of AF. 14,19 …”

Section: Conversion Ratementioning

confidence: 99%

“…Until the present, there have been four reports on the efficacy of amiodarone in the set-ting of new-onset AF, but the numbers of patients were relatively small and the reported amiodarone efficacy varied from 59 to 92% of patients. [6][7][8][9] The purpose of the present study was to assess the efficacy of intravenous amiodarone in conversion of AF in a randomized, single-blind, multicenter trial.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intravenous amiodarone for cardioversion of recent‐onset atrial fibrillation

Cybulski

Kułakowski

Budaj

et al. 2003

Clinical Cardiology

View full text Add to dashboard Cite

SummaryBackground: Atrial fibrillation (AF) is one of the most common causes of hospital admission, with a prevalence of up to 5% of the population, increasing with advancing age. Emergency direct current cardioversion is the therapy of choice when arrhythmia leads to hemodynamic compromise, but in patients who are hemodynamically stable, antiarrhythmic drugs are usually given to restore sinus rhythm.Hypothesis: The study was undertaken to assess the efficacy of intravenous amiodarone in cardioversion of recent-onset paroxysmal atrial fibrillation (AF). No standard antiarrhythmic therapy has been accepted for pharmacologic cardioversion of AF. Amiodarone seems to be a promising candidate, but only few randomized trials are available and the results are inconsistent.Methods: In all, 160 patients with AF lasting < 24 h were randomly assigned (2:1 fashion) to the amiodarone group (n = 106) receiving 5 mg/kg as a 30 min intravenous (IV) infusion, followed by IV infusion of 10 mg/kg during 20 h diluted in 1000 ml of 10% glucose with 20 IU of rapid-action insulin, 80 mEq of potassium chloride, and 8 g of magnesium sulphate (GIKM), or to the control group (n = 54) receiving 1000 ml of

show abstract

Section: Conversion Ratementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Intravenous amiodarone for cardioversion of recent‐onset atrial fibrillation

Cybulski

Kułakowski

Budaj

et al. 2003

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…[18,[50][51][52][53][54], Martinez-Marcos et al found the median time to conversion to be 25 minutes with a range of 4-660 minutes.…”

Section: Class Ic Antiarrhythmic Medications Flecainidementioning

confidence: 99%

“…The conversion for SVT with amiodarone has been reported to range from 47%-80% [52,78,80,81], with a median time to conversion of 5.5-8.7 hours [52,80,81].…”

Section: Class III Antiarrhythmic Medications Amiodaronementioning

confidence: 99%

Antiarrhythmic Medications for Cardioversion and Maintenance of Sinus Rhythm in Patients with Cardiac Arrhythmias: A Review of the Literature

En¹,

Sk²

2017

Cardiovasc Pharm Open Access

View full text Add to dashboard Cite

Introduction: Cardiac arrhythmias, including supraventricular and ventricular tachycardias, portend a higher risk of morbidity and mortality. These arrhythmias also are associated with increased healthcare resource utilization, decreased quality of life, and increased activity impairment. Pharmacologic conversion is a treatment option for conversion to sinus rhythm that has the advantage of avoiding sedation from DC cardioversion.

show abstract

“…In AF episodes lasting less than 48 hours cardio version rate for class IC and III drugs is approximately 60-80% 14 . In a randomised trial comparing flecainide, propafenone, and amiodarone for cardioversion of recent onset AF, conversion to sinus rhythm occurred in 90%, 72%, and 64% of patients respectively 15 . Class IC drugs (flecainide and propafenone) should be avoided in patients with underlying ischaemic heart disease or impaired left ventricular function.…”

Section: Pharmacological Cardioversionmentioning

confidence: 99%